Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2007

View Archived Issues

Outcome of Erbitux phase III study in first-line treatment of advanced lung cancer

Ariad and Merck & Co. enter global collaboration to jointly develop and market AP-23573

New therapeutic agents for psychiatric disorders reported in recent patents

Recent patents disclose novel treatments for inflammatory disorders

Patient enrollment begins for phase II IMC-A12 study in advanced colorectal cancer

Encysive Pharmaceuticals provides update on Thelin NDA

Tikvah Therapeutics completes private financing

LAB International changes name to Akela Pharma

Enrollment of phase IIa trial of MEM-3454 for AD completed

Enrollment of Dynavax's pivotal phase III trial of HBV vaccine completed

FDA accepts Collegium's IND for abuse deterrent, sustained release opioid

Jerini Ophthalmic's IND for JSM-6427 for AMD accepted by FDA

Valopicitabine program placed on hold in U.S.

Recent patents impart novel analgesic agents

New Alzheimer's disease remedy disclosed in recent Roche patent

ERCC1 mRNA measurement used to assign non-small cell lung cancer treatment

Clinical centers now being recruited for DIMOND study

RON receptor tyrosine kinase a potential pancreatic cancer target

Renal impairment implicated in progression to prediabetes

Selenium supplementation does not prevent type 2 diabetes

Diabetes incidence reduced in rheumatoid arthritis patients taking hydroxychloroquine

Bionomics advances development of potassium channel Kv1.3 blockers

Studies characterize direct thrombin inhibitor AZD-0837

Colostrinin launched in Australasia

Ceftobiprole filed in Canada for cSSSI

Neupro launched in U.S.

Testosterone MD-Lotion elevates testosterone levels into normal healthy range

Iclaprim achieves primary efficacy endpoint in phase III cSSSI trial

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Jan. 2, 2026.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
AND-017 increases RBC and hemoglobin in sickle cell disease
BioWorld Science
Sickle cell disease (SCD) is an inherited hemoglobinopathy caused by a mutation in the gene encoding β-globin that results in hemoglobin S polymerization, red...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...